The Dangers of the Puberty Blockers Ban: A Step Backwards for Trans Youth

The Dangers of the Puberty Blockers Ban: A Step Backwards for Trans Youth

I recently received an email from my MP, Rachel Taylor, regarding the government's decision to halt the use of puberty blockers for transgender young people while clinical trials are conducted. As someone who has been in close contact with Rachel for years, even before I resigned as the LGBT officer for Labour, I find myself deeply disappointed in her response. I had hoped that she would stand firmly against the harm this ban is causing, but unfortunately, her stance appears to be more about political appeasement than standing up for what is right.

In her email, Rachel states, “The issue of puberty blockers is of concern to me, because I want to make sure that all transgender young people have access to high-quality medical care and support, which at present remains woefully inadequate.” I too agree that access to high-quality medical care is essential, but the government's decision to halt these treatments is a direct step backward. Puberty blockers are not some experimental treatment but a well-established part of gender-affirming care, used to alleviate the distress of transgender youth who are at risk of further psychological harm. To delay their use based on the lack of long-term studies is to ignore the overwhelming support for their use in managing gender dysphoria, and it denies transgender youth timely care. In her own words, Rachel acknowledges that current healthcare access is “woefully inadequate”—so why support a decision that only worsens this disparity?

Moreover, Rachel mentions, “While I understand the strength of feeling in the trans community from those who attest to the benefits of puberty blockers, it remains of concern to me that the Cass Review found there is not enough evidence about the long-term impact of puberty blockers to know whether they are safe or effective.” This line is particularly troubling. While it’s essential to base medical decisions on evidence, delaying treatment based on the potential risks of something that has been widely used in healthcare for years is irresponsible. The Cass Review, which Rachel seems to lean on, has been widely criticized for its lack of solid evidence and its failure to provide a comprehensive, balanced view of the available research. The review’s conclusions were not based on rigorous scientific standards but rather on concerns that have not been substantiated by credible research. By placing such weight on a report that lacks clear evidence, we risk causing more harm than good, especially when there is ample data supporting the positive outcomes of puberty blockers in supporting transgender youth’s well-being.

Rachel also writes, “That is the basis upon which the Health Secretary has halted the use of puberty blockers among trans teenagers, while immediately acting to establish proper clinical trials that will gather the evidence we need.” While I agree that research is important, the delay in providing necessary healthcare while waiting for clinical trials to conclude is actively harmful. These young people cannot afford to wait for clinical trials to be completed—they need care now. This decision only prolongs their suffering and puts them at greater risk. The Health Secretary’s stance on this issue is not one that should be supported by anyone who truly cares about the well-being of trans youth.

I also find Rachel’s refusal to call out Wes Streeting, the Health Secretary, for his decision deeply disappointing. She says, “I was pleased to have been instrumental in setting up and taking part in the recent evidence session held by the Women and Equalities Select Committee to look at these complex issues and to challenge some of the more controversial areas of her report.” Yet, despite her involvement in these discussions, she remains silent when it comes to addressing the harm caused by this ban. Why isn’t she using her platform to speak out against the negative impact of Streeting’s decision? The trans community needs its allies to actively challenge harmful decisions, not just remain neutral.

What is most concerning is Rachel's silence on the matter on social media, something she has been careful to avoid in order to “not upset voters.” As she writes, “I want you to know that I will continue to raise poor access to healthcare, especially referral times and access to mental health support, for trans people in parliament.” However, this issue is not just about talking points—it’s about action. Human rights and the well-being of trans youth should always come before political popularity. By remaining silent, Rachel is feeding into the misinformation and hatred that trans people face. Silence is complicity, and by not addressing the harm of the puberty blockers ban, she is allowing it to continue unchecked.

At the end of the day, the rhetoric of “protecting women’s rights whilst also protecting trans rights” is a false equivalence that only serves to pit two marginalized groups against each other. As Rachel herself has said, “I fundamentally believe that there is nothing to stop us protecting women’s rights whilst also protecting trans rights and I reject the false choice that some have tried to create between the two.” This statement sounds good in theory, but in practice, it too often becomes a justification for policies that harm trans people while avoiding the more difficult work of standing up against harmful government decisions.

Transgender youth need access to puberty blockers and gender-affirming care, and we must not allow political considerations to stand in the way of their health and safety. Rachel Taylor’s silence on this issue is a significant failure to live up to her promise to fight for trans rights. I urge her, and all MPs, to reconsider their support for this ban. Silence is no longer an option. Trans youth need our support now more than ever.